Bio-techne — Investor Presentation (November 2019)

10 slides from Bio-techne's investor presentation, November 2019

Slide 2: Business Overview
ANTIBODIES PROTEINS BUSINESS 10% 5% 3% OVERVIEW INSTRUMENTS SERVICES R OYA LT I E S PRESIDENT AND CEO Chuck Kummeth CLINICAL HEADQUARTERS CONTROLS IMMUNOASSAYS Minneapolis, MN NUMBER OF EMPLOYEES ~2,235 WORLDWIDE PRESENCE TISSUE BIOPSY LIQUID BIOPSY 35 Locations FY2019 REVENUES $714M NASDAQ TECH 82
Slide 8: The Workflow: EPI prostate cancer test
THE WORKFLOW: URINE PAT E N T E D QRT-PCR M U LT I VA R I AT E R E S U LT: SAMPLE EXOSOMAL RNA A N A LY S I S ALGORITHMIC EXTRACTION A N A LY S I S An increasing EPI score correlates with greater risk of Algorithm high-grade prostate cancer (HGPCa) on biopsy PCA3 INTENDED USE: SPDEF The EPITM risk s
Slide 9: Revenue and Adjusted Operating Income targets
REVENUE A D J . O P E R AT I N G INCOME ~40% Rev CAGR OM% in 5 yrs • Analytical Solutions +15–20% • Analytical Solutions ~30% • Reagent Solutions +5–7% • Reagent Solutions +50% Protein Sciences +8–11% Protein Sciences Mid 40s% • Diagnostics +4–6% • Diagnostics ~30% • Genomics — ACD +20–30% • Genomic
Slide 10: Synergies
TISSUE BIOPSY LIQUID BIOPSY SYNERGIES CORE PRODUCTS: • ANTIBODIES • PROTEINS • I M M U N O A S S AY • C A L I B R AT I O R S & C E L L C U LT U R E & CONTROLS INSTRUMENTS – PROTEIN GENE THERAPY • SMALL MOLECULES A N A LY S I S SYNERGIES © 2019 Bio-Techne®. All rights reserved. 10